MX2015001250A - Composiciones y tratamiento para enfermedades y trastornos del ojo. - Google Patents

Composiciones y tratamiento para enfermedades y trastornos del ojo.

Info

Publication number
MX2015001250A
MX2015001250A MX2015001250A MX2015001250A MX2015001250A MX 2015001250 A MX2015001250 A MX 2015001250A MX 2015001250 A MX2015001250 A MX 2015001250A MX 2015001250 A MX2015001250 A MX 2015001250A MX 2015001250 A MX2015001250 A MX 2015001250A
Authority
MX
Mexico
Prior art keywords
compositions
disorders
treatment
eye diseases
methods
Prior art date
Application number
MX2015001250A
Other languages
English (en)
Other versions
MX362185B (es
Inventor
Wei-Wei Chang
Kenneth Sawyer
Original Assignee
Rhodes Technologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhodes Technologies filed Critical Rhodes Technologies
Publication of MX2015001250A publication Critical patent/MX2015001250A/es
Publication of MX362185B publication Critical patent/MX362185B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Abstract

La invención se relaciona a composiciones y métodos para tratar enfermedades y trastornos del ojo. Más específicamente, la invención proporciona composiciones que comprenden progesterona y métodos para tratar enfermedades y trastornos de la superficie ocular, que comprende aplicar las composiciones tópicamente.
MX2015001250A 2012-07-27 2013-07-26 Composiciones y tratamiento para enfermedades y trastornos del ojo. MX362185B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261676530P 2012-07-27 2012-07-27
US201361756321P 2013-01-24 2013-01-24
PCT/US2013/052264 WO2014018856A1 (en) 2012-07-27 2013-07-26 Compositions and treatment for eye diseases and disorders

Publications (2)

Publication Number Publication Date
MX2015001250A true MX2015001250A (es) 2015-10-22
MX362185B MX362185B (es) 2019-01-08

Family

ID=49997851

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015001250A MX362185B (es) 2012-07-27 2013-07-26 Composiciones y tratamiento para enfermedades y trastornos del ojo.

Country Status (20)

Country Link
US (2) US20150216877A1 (es)
EP (1) EP2877184B1 (es)
JP (1) JP6209777B2 (es)
KR (1) KR102097663B1 (es)
CN (2) CN107595857A (es)
AU (1) AU2013295645B2 (es)
BR (1) BR112015001847A8 (es)
CA (1) CA2880027C (es)
DK (1) DK2877184T3 (es)
ES (1) ES2759781T3 (es)
HK (1) HK1210968A1 (es)
HU (1) HUE046963T2 (es)
IL (1) IL236920B (es)
IN (1) IN2015DN00542A (es)
MX (1) MX362185B (es)
NZ (1) NZ704247A (es)
PL (1) PL2877184T3 (es)
PT (1) PT2877184T (es)
WO (1) WO2014018856A1 (es)
ZA (1) ZA201500561B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2014152385A2 (en) 2013-03-15 2014-09-25 Glia, Llc Cranial delivery of pharmaceuticals
WO2015080758A1 (en) * 2013-11-27 2015-06-04 Al-Qahtani Ahmed H Method and composition for the treatment of moderate to severe keratoconjunctivitis sicca
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
EP3171872B1 (en) 2014-07-21 2020-11-11 Glia, LLC Method for treating radiotherapy-and-chemotherapy associated cognitive or emotional impairment with cannabinoids
WO2016018993A1 (en) 2014-07-29 2016-02-04 Therapeuticsmd, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
KR101960023B1 (ko) * 2016-12-21 2019-03-20 김보경 이산화탄소 발생 장치
US20230091716A1 (en) * 2020-02-12 2023-03-23 Glia, Llc Progesterone Combinations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102656A (en) 1983-07-29 1992-04-07 The Mennen Company Antiperspirant creams
US4937069A (en) 1985-11-15 1990-06-26 Bristol-Myers Squibb Company Anhydrous semi-solid antiperspirant suspension
US5069897A (en) 1987-10-16 1991-12-03 The Proctor & Gamble Company Antiperspirant creams
US6659985B2 (en) 2002-01-30 2003-12-09 Southern College Of Optometry Method to use transdermal administration of androgens to the adnexa of the eye
US7572780B2 (en) 2003-01-21 2009-08-11 Dimera, Incorporated Method and kit for reducing the symptoms of peripheral vascular disease
US20080132475A1 (en) 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
JP5640207B2 (ja) * 2007-10-08 2014-12-17 セラオプティクスＴｈｅｒａｏｐｔｉｃｓ 水性眼用処方物
US20100016264A1 (en) * 2007-12-05 2010-01-21 Connor Charles G Treatment for dry eye using testosterone and progestagen
CN101757622A (zh) * 2008-11-28 2010-06-30 天津金耀集团有限公司 一种眼部抗炎的药物组合物
WO2011039638A2 (en) * 2009-10-02 2011-04-07 Foamix Ltd. Topical tetracycline compositions

Also Published As

Publication number Publication date
IL236920B (en) 2018-06-28
EP2877184A4 (en) 2016-03-30
AU2013295645A1 (en) 2015-02-05
US9925201B2 (en) 2018-03-27
US20150216877A1 (en) 2015-08-06
EP2877184B1 (en) 2019-09-04
MX362185B (es) 2019-01-08
BR112015001847A2 (pt) 2017-07-04
HUE046963T2 (hu) 2020-04-28
US20170189413A1 (en) 2017-07-06
NZ704247A (en) 2018-04-27
CN107595857A (zh) 2018-01-19
HK1210968A1 (en) 2016-05-13
PL2877184T3 (pl) 2020-04-30
CA2880027C (en) 2021-12-07
DK2877184T3 (da) 2019-12-09
CN104661663A (zh) 2015-05-27
JP6209777B2 (ja) 2017-10-11
KR102097663B1 (ko) 2020-04-06
KR20150038311A (ko) 2015-04-08
AU2013295645B2 (en) 2017-08-24
BR112015001847A8 (pt) 2021-09-08
EP2877184A1 (en) 2015-06-03
CA2880027A1 (en) 2014-01-30
ES2759781T3 (es) 2020-05-12
PT2877184T (pt) 2019-12-02
JP2015524434A (ja) 2015-08-24
WO2014018856A1 (en) 2014-01-30
ZA201500561B (en) 2016-04-28
IN2015DN00542A (es) 2015-06-26

Similar Documents

Publication Publication Date Title
MX362185B (es) Composiciones y tratamiento para enfermedades y trastornos del ojo.
AU2018236800B2 (en) DNA-PK inhibitors
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
PH12015500525A1 (en) Formulations of enzalutamide
EP4282479A3 (en) Use of pridopidine to treat depression or anxiety
UA114705C2 (uk) Андрогенна композиція для лікування офтальмологічного захворювання
IN2014DN06792A (es)
WO2012080497A3 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
MX2015003701A (es) Composiciones para tratamiento.
EP3086809A4 (en) Compositions and methods of treating ocular diseases
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
MX340536B (es) Terapia direccionada al receptor del factor de crecimiento epidermico (egfr).
PH12016500903A1 (en) Novel methods for treating neurodegenerative diseases
ZA202002075B (en) Compounds, compositions and methods for treatment of eye disorders and skin diseases
EP3265103A4 (en) Compositions and methods for treating ocular diseases
PH12017501694A1 (en) Compositions for the treatment of fibrosis and fibrosis-related diseases
EP3402511A4 (en) COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES
EP2569018A4 (en) HUMANIZED TTC AND METHOD FOR ITS USE
PH12015500852A1 (en) Method for treating eye disorders
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
AU2016349439A8 (en) Non-bioconvertible C3-substituted pregnenolone derivatives for use in the treatment of substance use disorders
PH12016500824A1 (en) Compositions and methods for the treatment of viral diseases with pde4 modulators
MA39718A (fr) Compositions et méthodes d'utilisation de celles-ci
EP3129054A4 (en) Methods and compositions for the treatment of ocular diseases and disorders

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: GLIA LLC

FG Grant or registration